ID: ALA29804

Max Phase: Preclinical

Molecular Formula: C14H11FO3

Molecular Weight: 246.24

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)Cc1ccccc1Oc1ccccc1F

Standard InChI:  InChI=1S/C14H11FO3/c15-11-6-2-4-8-13(11)18-12-7-3-1-5-10(12)9-14(16)17/h1-8H,9H2,(H,16,17)

Standard InChI Key:  LAVKHAMQQVBXLL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 246.24

Molecular Weight (Monoisotopic): 246.0692

AlogP: 3.25

#Rotatable Bonds: 4

Polar Surface Area: 46.53

Molecular Species: ACID

HBA: 2

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.75

CX Basic pKa:

CX LogP: 3.25

CX LogD: -0.03

Aromatic Rings: 2

Heavy Atoms: 18

QED Weighted: 0.90

Np Likeness Score: -0.84

References

1. Atkinson DC, Godfrey KE, Meek B, Saville JF, Stillings MR..  (1983)  Substituted (2-phenoxyphenyl)acetic acids with antiinflammatory activity. 1.,  26  (10): [PMID:6620297] [10.1021/jm00364a004]

2. Sablone MR, Cesta MC, Moriconi A, Aramini A, Bizzarri C, Di Giacinto C, Di Bitondo R, Gloaguen I, Aschi M, Crucianelli M, Bertini R, Allegretti M..  (2009)  Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.,  19  (15): [PMID:19560921] [10.1016/j.bmcl.2009.06.027]

Source

Source(1):

• Scientific Literature